Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNFα reached even 7-fold higher level in athletes and was highly correlated with CVD risk factor such as TG, lipoproteins LDL and HDL as well as CRP.
|
31220998 |
2020 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mean serum level of TNF-α and IL1-α were 32.16 pg/ml and 6.64 pg/ml in CVD patient.
|
31485173 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, it was concluded that TNF-α and IL-8 may be involved in the occurrence and development of OSAHS, are closely related to OSAHS and may be important risk factors for cardiovascular disease in patients with OSAHS.
|
30783447 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this systematic review and meta-analysis was to investigate omega-3 fatty acids' influence on 12 inflammatory biomarkers-LDL, HDL, total cholesterol, TG, HbA1c, Apo AI, Apo AII, Apo B, CRP, TNF-α, glucose, and fasting blood glucose among diabetic and cardiovascular disease (CVD) patients.
|
31827125 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aims to assess the association between circulating inflammatory biomarkers TNF receptors (TNFRs) and the risk of renal disease progression, cardiovascular disease (CVD) events, and mortality in patients with diabetes.
|
31813103 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Biologic inhibitors of tumor necrosis factor-α may be beneficial in preventing cardiovascular disease because tumor necrosis factor-α promotes the initiation and progression of atherosclerosis.
|
31208307 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor-α (TNFα) is a proinflammatory cytokine that is closely linked to the development of cardiovascular disease.
|
30925081 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
ZBTB12 hypomethylation is linked to shorter TNF-ɑ stimulated whole blood coagulation time and increased WBC and granulocyte counts, further elucidating the possible link between ZBTB12 methylation and cardiovascular disease risk.
|
31077224 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The biological link between depression, inflammation, and CVD can be related to high levels of pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6, released by macrophages which play a central role in the pathophysiology of both depression and CVD.
|
31296155 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A set of inflammation-related biomarkers was used as outcome: a pro/anti-inflammatory interleukins ratio, TGFβ-1, C-reactive protein, TNF-α, 3 cell adhesion molecules, and 3 types of immune cells; gamma-glutamyltransferase (GGT) and homocysteine were used as cardiovascular disease risk biomarkers, and alanine transaminase (ALT) as liver dysfunction biomarker.
|
29948222 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Obesity is accompanied by adipose tissue remodeling characterized by increased production of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, leptin and resistin and reduced secretion of adiponectin, which favors inflammation, metabolic disorders, and cardiovascular diseases.
|
31037597 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings showed that exercise and anti-TNF had differential effects on CVD risk in RA, and should be combined for optimal CVD risk reduction.
|
30421104 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) are candidate blood biomarkers of cardiovascular disease (CVD).
|
31279001 |
2019 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, reduction of TNF-α levels below baseline raises concern regarding its use as prophylactic or preventive adjunct therapy in cardiovascular disease.
|
30813472 |
2019 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to determine the associations of leptin, adiponectin (ADA), tumor necrosis factor α (TNF‑α), and irisin levels with the diagnosis of atrial fibrillation (AF) on admission to the hospital as well as parameters of transthoracic echocardiography among inpatients with cardiovascular diseases (CVDs).
|
31553329 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Key publications provided data on classification criteria, disease prevalence, patterns of clinical and radiographic presentation, disease outcomes, associated cardiovascular disease risk, immunologic features and HLA associations, and efficacy and therapeutic benefit of TNFα inihbitors, interleukin-12/23 antagonists, and sulfasalazine.
|
30315571 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To assess the effect of tumor necrosis factor inhibitors (TNFi) on subclinical cardiovascular disease in patients with psoriatic disease.
|
29088580 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
12 wk of supplementation with resistant starch reduced the inflammatory marker TNF-α and heart rate, but it did not significantly improve glycemic control and other cardiovascular disease risk factors, in adults with prediabetes.
|
30010698 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the numerous molecules that are being studied for their potential utility as biomarkers of cardiovascular diseases, much interest has been shown in the superfamily of tumor necrosis factor (TNF) receptors.
|
28867452 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Awareness of the role of inflammation in CVD in patients with chronic inflammatory diseases and the potential for anti-inflammatory therapy, e.g., with tumor necrosis factor-α inhibitors, to also reduce atherosclerotic CVD has evolved into guideline- based recommendations.
|
29318966 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the cardiovascular safety of abatacept (ABA) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients with and without underlying cardiovascular disease (CVD).
|
29764964 |
2018 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLE patients with CVD had higher levels of Fas, TNF receptor 1, TRAIL receptor 2, MMP-1 and -7 than those without CVD.
|
29407876 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Soluble receptors for tumor necrosis factor alpha (sTNFR1 and sTNFR2) have been associated with cardiovascular diseases, and some evidence points towards a difference in associated risk between men and women.
|
29547707 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of mediators of cholesterol transport, namely the lectin-like oxidized low-density lipoprotein receptor (LOX)-1 and ATP-binding cassette transporter (ABCA)-1, inflammatory markers tumor necrosis factor (TNF)-α and interleukin (IL)-1β/IL-6, nuclear-factor kappa-light-chain-enhancer of activated B cells (NF-κB), intracellular/vascular adhesion molecule(s) (VCAM-1, ICAM-1), and miRNAs (miR-221/-21/-1), associated with cardiovascular disease (CVD), were analyzed in cardiac tissue and coronary vasculature.
|
30081225 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with manifold consequences for mammalian pathophysiology, including cardiovascular disease.
|
29617535 |
2018 |